Amy Haught
Nurse Practitioner · South Charleston, WVNPI 1043545155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 715 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 27.8% of the total. Reporting peaked in 2022 at $3,136 and has fallen 70.8% since, to $917 in 2025. Among nurse practitioner clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 715 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$1K
- Pfizer$518
- Ardelyx, Inc.$490
- plus $3K from 23 others
What the payments were for
- Food & beverage$11,39097%
- Education$2933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 234 | $3,249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 122 | $1,762 |
| Takeda Pharmaceuticals U.S.A., Inc. | 84 | $1,273 |
| Johnson & Johnson | 39 | $1,213 |
| Pfizer | 29 | $518 |
| Ardelyx, Inc. | 30 | $490 |
| Intercept Pharmaceuticals, Inc. | 24 | $380 |
| Redhill Biopharma Inc. | 30 | $365 |
| Gilead | 20 | $362 |
| Ironwood Pharmaceuticals, Inc | 18 | $303 |
| QOL Medical, LLC | 18 | $299 |
| Bristol Myers Squibb | 11 | $184 |
| Sanofi | 6 | $167 |
| Merck | 8 | $139 |
| Nestle Healthcare Nutrition Inc. | 2 | $127 |
| Regeneron Healthcare Solutions, Inc. | 5 | $121 |
| Daiichi Sankyo Inc. | 6 | $110 |
| Aimmune Therapeutics, Inc. | 5 | $106 |
| Janssen Scientific Affairs, LLC | 1 | $88 |
| Evoke Pharma, Inc. | 5 | $78 |
| Celltrion USA Inc. | 3 | $77 |
| Madrigal Pharmaceuticals | 4 | $71 |
| Axonics, Inc. | 3 | $49 |
| Boehringer Ingelheim | 2 | $40 |
| Novo Nordisk | 2 | $30 |
| Amgen | 1 | $29 |
| Lilly USA, LLC | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,683 in reported general payments places this provider in the 95th percentile of 649 nurse practitioner providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 43 | $130,795 |
| CreonLipase/Protease/Amylase | 30 | $69,228 |
| LinzessLinaclotide | 50 | $67,648 |
| RezdiffraResmetirom | 12 | $47,441 |
| TrulancePlecanatide | 20 | $13,512 |
| Mesalamine | 15 | $8,886 |
| Colestipol Hcl | 100 | $8,859 |
| Lubiprostone | 51 | $7,085 |
| MovantikNaloxegol Oxalate | 13 | $5,440 |
| Ursodiol | 43 | $4,224 |
| Mesalamine ErMesalamine | 14 | $4,040 |
| Famotidine | 349 | $3,400 |
| Pantoprazole Sodium | 228 | $3,077 |
| Tenofovir Disoproxil Fumarate | 13 | $2,919 |
| Omeprazole | 208 | $2,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,762 | $144,30763 claims |
| AbbVieCreon, Linzess | $3,249 | $136,87680 claims |
| Madrigal PharmaceuticalsRezdiffra | $71 | $47,44112 claims |
| Redhill Biopharma Inc.Movantik | $365 | $5,44013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 649 nurse practitioner providers in West Virginia.
Other nurse practitioner in South Charleston
- Rachel BrillSouth Charleston$16K
- Kelly HughartSouth Charleston$13K
- Renetta BrewerSouth Charleston$5K
- Leigh BrooksPrinceton$75K
- Destiny HowardBeckley$35K
- Rachael RigginsBeckley$19K
- Lacy HowardWheeling$18K
- Robin BlumeBeckley$18K
- Kellie VaughtBeckley$17K
- Lisa WalkerBeckley$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.